4 Value Stocks to Buy as Fed Rate Hikes Test Wall Street

The Federal Reserve raised its benchmark rate 25bps to a 3.75%-4.00% target range, its first increase since 2023, triggering a 631.2-point (1.2%) Dow decline and a 0.45% drop in the S&P 500. With inflation still above the Fed's 2% target—partly due to Middle East conflict-driven oil prices—the Fed signaled another hike could come before year-end, keeping policy restrictive. Zacks highlights Avnet, Centene, Signet and Lifetime Brands as value-screen candidates, citing favorable cash-flow valuations, Rank #1 or #2 ratings, and projected EPS growth ranging from 21.9% to 156.8%.

Analysis

The screened cohort is not a coherent rates trade: AVT and SIG retain meaningful cyclicality, while CNC is primarily exposed to medical-cost trend, policy reimbursement, and execution. A higher discount rate can favor near-term cash generators only if estimates hold; it does not protect against a demand-led earnings reset. The relevant distinction over the next 1-3 months is balance-sheet and working-capital quality, not a static price-to-cash-flow multiple.

AVT is the most interesting second-order beneficiary if enterprise/industrial component demand is stabilizing, but distributor cash flow can be flattered by inventory liquidation and supplier-payment timing. Require evidence of inventory turns improving without gross-margin erosion before underwriting a rerating; otherwise AVT is a late-cycle value trap despite apparent earnings leverage. SIG faces the opposite setup: discretionary jewelry demand and promotional intensity can deteriorate quickly if real consumer spending weakens, with diamond-price deflation potentially requiring further markdowns and impairing merchandise margins.

CNC offers the cleanest defensive earnings profile of the four, but its valuation case hinges on whether utilization and ACA/Medicaid mix remain within pricing assumptions. The contrarian risk is that crowded "defensive value" ownership makes even a modest medical-loss-ratio guide-up a multiple-compression event. LCUT is too small and illiquid for core capital deployment; its operating leverage is real, but import costs, freight, retailer inventory decisions, and refinancing capacity can dominate the equity outcome.

Consensus appears to conflate low P/CF with durable free cash flow. In a restrictive-rate regime, cash conversion after interest, inventory investment, and lease obligations matters more than operating cash flow, especially for distribution and consumer-product names. There is no standalone catalyst in this screen; use upcoming earnings and guidance as the decision points rather than chase a factor-label bid.

Key Decisions for Investors

• Initiate a 3-6 month long CNC / short SIG pair, sized beta-neutral: CNC should be relatively insulated from consumer discretionary pressure, while SIG is more exposed to traffic, promotions, and inventory markdowns. Target 10-15% relative return; exit if SIG maintains merchandise margin and raises full-year comparable-sales guidance, or if CNC raises its medical-cost outlook.
• Keep AVT on a 1-3 month earnings watch rather than buy immediately. Go long only if management confirms sequential inventory normalization, stable gross margin, and positive operating cash conversion; use a 7-10% stop below entry and target a 15% rerating. A renewed semiconductor inventory correction or receivables build falsifies the thesis.
• Avoid LCUT for scalable portfolio exposure despite apparent earnings leverage; establish only a small event-driven position if next results demonstrate positive free cash flow after working capital and no incremental liquidity stress. Treat weak volume and refinancing disclosures as a hard no-go signal.
• Use XLY puts or a modest XLY short as a 1-3 month hedge against the SIG leg rather than assuming all low-multiple consumer equities are rate-resistant. Reduce the hedge if retail sales and real wage data reaccelerate or SIG reports improving bridal and fashion-jewelry demand.